Market capitalization | $2.13b |
Enterprise Value | $2.15b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 16.12 |
EV/Sales (TTM) EV/Sales | 2.02 |
P/S ratio (TTM) P/S ratio | 2.00 |
P/B ratio (TTM) P/B ratio | 1.73 |
Revenue growth (TTM) Revenue growth | -10.26% |
Revenue (TTM) Revenue | $1.06b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
10 Analysts have issued a Omnicell, Inc. forecast:
10 Analysts have issued a Omnicell, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,064 1,064 |
10%
10%
|
|
Gross Profit | 441 441 |
15%
15%
|
|
EBITDA | 142 142 |
83%
83%
|
EBIT (Operating Income) EBIT | -22 -22 |
13%
13%
|
Net Profit | -18 -18 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.
Head office | United States |
CEO | Randall Lipps |
Employees | 3,650 |
Founded | 1992 |
Website | www.omnicell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.